Doctors reveal hidden danger for some Ozempic, Wegovy users with brain disorders
Once the semaglutide was discontinued at the advice of medical professionals, the patient’s rapid physical decline stabilized.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Andrews pointed out that this published documentation, alongside retrospective cohort data of ALS patients with diabetes, provides growing evidence that clinicians must be careful and thoughtful about who they treat with GLP-1 receptor agonists.
While weight-loss medications offer significant benefits for many patients, experts say maintaining body weight and muscle mass remains an important consideration for people with neurodegenerative diseases.
Healthcare providers should be highly cautious and context-aware when prescribing GLP-1 receptor agonists to patients with underlying neurodegenerative diseases, a neurologist cautioned. (iStock)
“Patient safety is of utmost importance to Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously,” Ambre James-Brown, global head and AVP of global media at Novo Nordisk, maker of Ozempic and Wegovy, told Fox News Digital.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“It’s important to note that ALS and other neurodegenerative diseases are not listed adverse reactions or warnings and precautions in the prescribing information for our semaglutide products, including Ozempic or Wegovy,” he added.
Khloe Quill is a lifestyle writer with Fox News Digital. She and the lifestyle team cover a range of story topics including food and drink, travel, and health.
Article source: https://www.foxnews.com/health/doctors-reveal-hidden-danger-ozempic-wegovy-users-brain-disorders